lilly mazdutide vs novo semaglutide Nordisk's obesity-drug business has exploded in just a few years. Between 2021 and 2025, the company's sales in this segment jumped roughly tenfold: from $1.3 billion to $12.4 billion, driven largely Lilly's Mounjaro triggers more weight

The risk of hypoglycaemia with GLP-1 medications is generally low unless they are used in combination with insulin or sulfonylureas

Some providers use a strategy of periodic medication courses rather than continuous treatment, though this approach has not been well studied in clinical trials

While Ozempic is FDA-approved for type 2 diabetes and to reduce cardiovascular risk, its active ingredient, semaglutide, is also widely used off-label for chronic weight management

This approach demonstrated long-term therapeutic effect in a dietary-induced obesity mouse model, offering a promising one-shot genome-editing therapy for non-genetic and complex diseases

in The Lancet in 2023

All three compounds belong to the same broad family of incretin-mimetic peptides, but they target different combinations of receptors